- Report
- May 2024
- 135 Pages
Global
From €5929EUR$6,499USD£5,067GBP
- Report
- June 2024
- 200 Pages
Global
From €7252EUR$7,950USD£6,199GBP
- Report
- January 2022
- 60 Pages
Global
From €3603EUR$3,950USD£3,080GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1368EUR$1,500USD£1,170GBP
- Report
- January 2022
- 60 Pages
Global
From €3603EUR$3,950USD£3,080GBP
- Report
- May 2022
- 43 Pages
Global
From €1824EUR$2,000USD£1,559GBP
- Report
- January 2025
- 132 Pages
Global
From €867EUR$950USD£741GBP
- Report
- March 2022
- 180 Pages
Global
From €2207EUR$2,419USD£1,886GBP
€3153EUR$3,456USD£2,695GBP
The Subarachnoid Hemorrhage Drug market is a subset of the Cardiovascular Drugs market. It is composed of drugs used to treat subarachnoid hemorrhage, a type of stroke caused by bleeding in the space between the brain and the thin tissues that cover it. These drugs are used to reduce the risk of further bleeding, reduce the risk of complications, and improve the patient's overall prognosis. Commonly used drugs include anticoagulants, antiplatelet agents, and vasopressors.
The Subarachnoid Hemorrhage Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies include Bristol-Myers Squibb, AstraZeneca, and Bayer. Show Less Read more
